Abstract | BACKGROUND: RESEARCH DESIGN: A liposomal delivery system, co-encapsulating DOX, and RAN-IP, was prepared using a thin-film rehydration technique. Dual-loaded liposomes were optimized by systematic modification of formulation variables. Real-Time-Polymerase Chain Reaction was used to determine Ran- GTP mRNA expression. In vitro cell lines were used to evaluate the effect of loaded liposomes on the viability of breast and lung cancer cell lines. In vivo testing was performed on a murine Solid Ehrlich Carcinoma model. RESULTS: RAN-IP reversed the Ran-expression-mediated MDR by inhibiting the Ran DNA damage repair function. Co-administration of RAN-IP enhanced sensitivity of DOX in breast cancer cell lines. Finally, liposome-mediated co-delivery with RAN-IP improved the anti- tumor effect of DOX in tumor-bearing mice when compared to single therapy. CONCLUSIONS: This study is the first to show the simultaneous delivery of RAN-IP and DOX using liposomes can be synergistic with DOX and lead to tumor regression in vitro and in vivo.
|
Authors | Yusuf Haggag, Bayan Abu Ras, Yahia El-Tanani, Murtaza M Tambuwala, Paul McCarron, Mohammed Isreb, Mohamed El-Tanani |
Journal | Expert opinion on drug delivery
(Expert Opin Drug Deliv)
Vol. 17
Issue 11
Pg. 1655-1669
(11 2020)
ISSN: 1744-7593 [Electronic] England |
PMID | 32841584
(Publication Type: Journal Article)
|
Chemical References |
- Drug Carriers
- Liposomes
- Peptides
- Doxorubicin
|
Topics |
- Animals
- Breast Neoplasms
(drug therapy)
- Cell Line, Tumor
- Doxorubicin
(administration & dosage)
- Drug Carriers
(chemistry)
- Drug Delivery Systems
- Drug Resistance, Multiple
(drug effects)
- Female
- Humans
- Liposomes
- MCF-7 Cells
- Mice
- Mice, Inbred BALB C
- Peptides
(administration & dosage)
|